{
    "nctId": "NCT06050109",
    "briefTitle": "The Benefits of Continued Use of Ovarian Function Suppression After 5 Years",
    "officialTitle": "A Multicenter, Open-label, Non-randomized Controlled Real World Study Comparing the Benefits of Continued Use of Ovarian Function Suppression After 5 Years",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer Female, Endocrine Therapy",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 1200,
    "primaryOutcomeMeasure": "invasive disease-free survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosed with early primary breast cancer\n* Female aged 18-60 years (including 18 year and 60 year)\n* Hormone receptor (HR) positive HER2 negative\n* Receive 5 years of OFS treatment\n* ECOG score 0-1\n* Voluntarily join this study and sign the informed consent form;\n* The researcher believes that it can benefit.\n\nExclusion Criteria:\n\n* The patient is receiving treatment that affects OFS at the same time The patient has received OFS treatment for less than 5 years\n* Central nervous system metastases with known obvious symptoms, such as headache, cerebral edema, blurred vision\n* Invasive metastases with known obvious symptoms\n* Invasive metastases with known obvious symptoms\n* Doctors think it is not suitable for inclusion",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT"
}